Related Experiment Video
Updated: Aug 15, 2026

Methods to Evaluate Cytotoxicity and Immunosuppression of Combustible Tobacco Product Preparations
Published on: January 10, 2015
Expanding treatment of tobacco dependence
Debra S Harris1, Robert M Anthenelli
1Mental Health Care Line (116-A), Cincinnati Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA.
Abstract:
Nicotine dependence is the leading preventable cause of adult morbidity and mortality in the world. New research on the treatment of this disorder ranges from studies evaluating access to treatment to studies elucidating the molecular mechanisms of nicotine addiction. As our understanding of the neurobiology of tobacco addiction grows, the number of potential therapeutic targets by which we can intervene in this pernicious disorder also increases. This paper presents an overview of recent research trends in the treatment of tobacco dependence. We review several novel mechanisms of action that may serve as therapeutic targets for the pharmacologic treatment of tobacco dependence, including drugs that affect monamine oxidase, selective nicotinic receptors, glutamate and gamma-aminobutyric acid receptors, and the endocannabinoid system. For each of these therapeutic targets, we discuss medications in development that affect these pathophysiologic mechanisms.
Insights
New research explores novel therapeutic targets for nicotine dependence, a major public health issue. Treatments focus on the neurobiology of tobacco addiction, including medications affecting neurotransmitter systems.
Area of Science:
- Neuroscience
- Pharmacology
- Addiction Medicine
Background:
- Nicotine dependence is a primary cause of preventable adult morbidity and mortality globally.
- Understanding the neurobiology of tobacco addiction is crucial for developing effective treatments.
Purpose of the Study:
- To provide an overview of recent research trends in treating tobacco dependence.
- To highlight novel therapeutic targets and medications in development for nicotine addiction.
Main Methods:
- Review of current scientific literature on nicotine dependence treatments.
- Analysis of emerging pharmacologic targets and their mechanisms of action.
Main Results:
- Identified several novel mechanisms for pharmacologic intervention in nicotine dependence.
- Discussed medications targeting monoamine oxidase, nicotinic receptors, glutamate, GABA, and the endocannabinoid system.
Conclusions:
- Advances in understanding neurobiology offer new therapeutic avenues for nicotine dependence.
- Several novel drug candidates show promise for treating tobacco addiction.
Related Concept Videos
Drug Dependence
CNS Depressants: Alcohol and Nicotine
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
